文献速递浆细胞疾病造血干细胞移植与细胞治疗

复发/难治性多发性骨髓瘤BCMA靶向CAR-T(ARI0002h)治疗中[18F]FDG-PET/CT的临床影响

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma.
PubMed 文献 · Blood Adv · 2025-01-01

纳入63例复发/难治性多发性骨髓瘤患者(CARTBCMA-HCB-01试验或同情用药),中央审阅5家中心基线[18F]FDG-PET/CT,评估软组织浆细胞瘤对疗效、生存和安全性的影响。52.4%患者基线有浆细胞瘤(21例仅骨旁、12例髓外)。有无浆细胞瘤者疗效无显著差异,但髓外病变者PFS和OS显著缩短;第100天PET/CT应答(Bologna标准)可预测生存,基线代谢肿瘤体积≥25 cm3与更早进展和更短OS相关。

要点

  • 基线有髓外浆细胞瘤者PFS和OS显著短于无髓外病变者。
  • 第100天[18F]FDG-PET/CT应答(Bologna标准)可预测生存结局。
  • 基线代谢肿瘤体积≥25 cm3与更早疾病进展和更短OS相关。

核心结论

  • 结果强调CAR-T回输前后用[18F]FDG-PET/CT评估髓外病变的重要性。

研究设计与样本

  • 研究纳入63例复发/难治性多发性骨髓瘤患者,接受CARTBCMA-HCB-01临床试验中的ARI0002h(学术性BCMA靶向CAR-T)治疗或同情用药。
  • 中央审阅5家参与中心的基线[18F]FDG-PET/CT,评估软组织受累(髓外和骨旁浆细胞瘤)对疗效、生存和安全性影响。

主要发现

  • 63例中52.4%在入组时有浆细胞瘤(21例仅骨旁,12例髓外)。
  • 有无浆细胞瘤患者之间疗效无显著差异。
  • 国际骨髓瘤工作组应答与第100天[18F]FDG-PET/CT应答(Bologna标准)之间存在相关性。
  • 有无浆细胞瘤患者之间PFS或OS无差异,但髓外病变者PFS和OS均显著缩短。
  • 基线[18F]FDG-PET/CT代谢肿瘤体积≥25 cm3与更早疾病进展和更短OS相关。

关键数值与推荐

  • 第100天[18F]FDG-PET/CT应答按Bologna标准评估,可预测生存结局。
  • 基线代谢肿瘤体积≥25 cm3与更早疾病进展和更短OS相关。

临床怎么用

  • 原文结论强调CAR-T回输前后用[18F]FDG-PET/CT评估髓外病变的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poorly understood. This study included 63 patients with relapsed/refractory MM treated either in the CARTBCMA-HCB-01 clinical trial (ARI0002h; academic B-cell maturation antigen [BCMA]-targeted CAR T-cell therapy) or in compassionate use. The aim was to evaluate the impact of soft-tissue involvement (extramedullary [EMD] and paraskeletal [PS] plasmacytomas) in response, survival and safety. Baseline [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) from 5 participating centers were reviewed centrally. Of 63 patients, 52.4% presented plasmacytomas at the time of inclusion (21 PS, exclusively; and 12 EMD). Per responses, there were no significant differences between patients with and without plasmacytomas. A correlation was present between International Myeloma Working Group responses and those obtained by [18F]FDG-PET/CT at day 100 (Bologna criteria). No differences were observed in progression-free survival (PFS) or overall survival (OS) between patients with or without plasmacytomas. However, both PFS and OS were significantly shorter in patients with EMD. Interestingly, [18F]FDG-PET/CT response assessed on day 100, in accordance with the Bologna criteria, was predictive of survival outcomes. A metabolic tumor volume of ≥25 cm3 at baseline [18F]FDG-PET/CT was associated with earlier disease progression and shorter OS. These results highlight the importance of EMD evaluation by [18F]FDG-PET/CT before and after CAR T-cell infusion. This trial was registered at www.ClinicalTrials.gov as #NCT04309981; and EudraCT, 2019-001472-11.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zugasti I, Tormo-Ratera M, Oliver-Caldés A, et al. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Adv. 2025. PMID: 39602341. doi:10.1182/bloodadvances.2024014360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。